OSI Pharmaceuticals clinical trials

Acquired by Astellas Pharma Inc, Jun 3, 2010 · source ↗

The registry lists 16 studies whose lead sponsor is OSI Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 12, 2024.

Studies

Recruiting first, then most recently updated. Showing 16 of 16. All Astellas Pharma Inc studies →

• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric EpendymomaTerminatedNCT01032070Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205TerminatedNCT01247922Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted after OSI Pharmaceuticals became part of Astellas Pharma Inc

• Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerCompletedNCT01010945Phase 1

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic FunctionCompletedNCT00139620Phase 1

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00072631Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid TumorsCompletedNCT00033241Phase 1

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.CompletedNCT00040183Phase 3

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00036647Phase 3

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsCompletedNCT00373425Phase 3

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLCCompletedNCT00294762Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2CompletedNCT00085839Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy RegimensCompletedNCT00294736Phase 1

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid TumorsCompletedNCT00116896Phase 1

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line TherapyCompletedNCT00116909Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) CancerCompletedNCT00073502Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc

• A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract CancerCompletedNCT00088270Phase 2

  Sponsor listed in the registry: OSI Pharmaceuticals · First submitted before OSI Pharmaceuticals became part of Astellas Pharma Inc